Skip to Content

Posts tagged with "Drug Assays"

  • Academia (vs. Industry)

    More Hot Air From Me on Screening

    After yesterday’s post on pathway patents, I figured that I should talk about high-throughput screening in academia. I realize that there are some serious endeavors going on, some of them staffed by ex-industry people. So I don’t mean to come across as thinking that academic screening is useless, because it certainly isn’t. What i… Read More
  • Drug Assays

    Want To Screen Pfizer’s Compounds? Sign Here.

    I’ve heard that Pfizer is doing something unusual with its proprietary compound collection: they’re offering to let other people screen it. Now, that’s quite a step. Most companies guard their compounds pretty closely, considering them to be key assets. But I’m told that Pfizer has been meeting with several other (mostly sma… Read More
  • Biological News

    No MAGIC Involved

    What a mess! Science has a retraction of a 2005 paper, which is always a nasty enough business, but in this case, the authors can’t agree on whether it should be retracted or not. And no one seems to be able to agree on whether the original results were real, and (even if they weren’t) Read More
  • Drug Assays

    Drugs For Bacteria: Really That Hard, Or Not?

    A few readers have told me that I’m being too hard on antibacterial drug discovery, at least on target-based efforts in the field. The other day I asked if anyone could name a single antibacterial drug on the market that had been developed from a target, rather than by screening or modification of existing drugs… Read More
  • Analytical Chemistry

    Tie Me Molecule Down, Sport

    There are a huge number of techniques in the protein world that relay on tying down some binding partner onto some kind of solid support. When you’re talking about immobilizing proteins, that’s one thing – they’re large beasts, and presumably there’s some tether that can be bonded to them to string off to a solid… Read More
  • Drug Assays

    Structure-Activity: Lather, Rinse, and Repeat

    Medicinal chemists spend a lot of their time exploring and trying to make sense of structure-activity relationships (SARs). We vary our molecules in all kinds of ways, have the biologists run them through the assays, and then sit down to make sense of the results. And then, like as not, we get up again after… Read More
  • Drug Assays

    The Hideous Numbers of Compounds

    I was blithely throwing around the term “chemical space” in yesterday’s post. So, what am I talking about, and how much room is in there, anyway? Let’s narrow it down to organic compounds, to start with, or at least compounds that are mostly organic. A working definition, as far as people interested in biology and… Read More
  • Chemical News

    Diversity-Oriented Synthesis: Oriented The Right Way?

    Ever hear of Diversity-Oriented Synthesis? It’s an odd bird. DOS tries to maximize the number of structures and scaffolds produced from a given synthetic scheme – to find the most efficient ways to populate the largest amount of chemical space. In a way, it’s the contrapositive of natural product synthesis, which focuses all its effort… Read More
  • Drug Assays

    Sticking It to Proteins

    So, you’re making an enzyme inhibitor drug, some compound that’s going to go into the protein’s active site and gum up the works. You usually want these things to be potent, so you can be sure that you’ve knocked down the enzyme, so you can give people a tiny, convenient pill, and so you don’t… Read More
  • Biological News

    Wash Your Tubes; Mess Up Your Data

    I wrote a while back about the problem of compounds sticking to labware. That sort of thing happens more often than you’d think, and it can really hose up your assay data in ways that will send you running around in circles. Now there’s a report in Science of something that’s arguably even worse. (Here’s… Read More
...293031...